Convergent Therapeutics – Next Generation Radiopharmaceutical Therapies for Cancer

Dr. Philip Kantoff, Co-founder and CEO of Convergent Therapeutics, a clinical-stage pharmaceutical company focused on developing next-generation radiopharmaceutical therapies for cancer discusses the development of a radio-antibody, CONV01-α, a first-in-class Actinium-linked prostate-specific membrane antigen (PSMA)-targeted antibody. In a Phase 1 Single Ascending Dose trial of CONV01-α in men with prostate cancer, most patients responded and 44% of the patients experienced a greater than 50% decline in prostate-specific antigen (PSA) levels after receiving only a single dose of CONV01-α.

Dr. Philip Kantoff was appointed the Chief Executive Officer of Convergent Therapeutics on July 1, 2021. Prior to joining Convergent, Dr. Kantoff spent six years as Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center, where he directed a department of approximately 500 physicians and physician-scientists, caring for cancer patients and developing improved testing and cancer therapies. He is the Emeritus Jerome and Nancy Kohlberg Chair in Medicine at Harvard Medical School. At Dana Farber Cancer Institute (DFCI), he was the Chief of the Solid Tumor Oncology Division, and he served as Director of the Lank Center for Genitourinary Oncology at the DFCI. In those positions, Dr. Kantoff created robust programs of clinical care and research as well as laboratory research. During this time, he served as a clinical researcher and principal investigator in significant trials devoted to the development of new therapeutic targets for men with advanced prostate cancer and, throughout his tenure at DFCI, he helped to set broad clinical research priorities.

Dr. Kantoff is a member of numerous professional societies and editorial boards, has written more than 500 articles and books and has lectured throughout the world. Among his significant accomplishments, Dr. Kantoff was honored with the Baruj Benacerraf Clinical Investigator Award from 1994 to 1997 and the Harvard Medical School Kantoff-Sang Lectureship Award from 2011 through the present time. He was also recognized with the first Prostate Cancer Foundation Mentor of Excellence Award and has been named to the second-year class of “Giants in Cancer Care.” He was inducted into the Association of American Physicians in 2017. Dr. Kantoff is board certified in internal medicine and medical oncology. He completed his research fellowship at the National Institutes of Health and his medical oncology fellowship at the Dana-Farber Cancer Institute.